294 related articles for article (PubMed ID: 35704974)
41. Peptide-Affinity Precipitation of Extracellular Vesicles and Cell-Free DNA Improves Sequencing Performance for the Detection of Pathogenic Mutations in Lung Cancer Patient Plasma.
Taylor C; Chacko S; Davey M; Lacroix J; MacPherson A; Finn N; Wajnberg G; Ghosh A; Crapoulet N; Lewis SM; Ouellette RJ
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260345
[TBL] [Abstract][Full Text] [Related]
42. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
43. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
44. NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?
Falk AT; Heeke S; Hofman V; Lespinet V; Ribeyre C; Bordone O; Poudenx M; Otto J; Garnier G; Castelnau O; Guigay J; Leroy S; Marquette CH; Hofman P; Ilié M
Expert Rev Anticancer Ther; 2017 Aug; 17(8):681-685. PubMed ID: 28511612
[TBL] [Abstract][Full Text] [Related]
45. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.
Papadopoulou E; Tsoulos N; Tsantikidi K; Metaxa-Mariatou V; Stamou PE; Kladi-Skandali A; Kapeni E; Tsaousis G; Pentheroudakis G; Petrakis D; Lampropoulou DI; Aravantinos G; Varthalitis I; Kesisis G; Boukovinas I; Papakotoulas P; Katirtzoglou N; Athanasiadis E; Stavridi F; Christodoulou C; Koumarianou A; Eralp Y; Nasioulas G
PLoS One; 2019; 14(12):e0226853. PubMed ID: 31860648
[TBL] [Abstract][Full Text] [Related]
46. Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.
Jiang J; Adams HP; Lange M; Siemann S; Feldkamp M; McNamara S; Froehler S; Yaung SJ; Yao L; Balasubramanyam A; Tikoo N; Ju C; Achenbach HJ; Krügel R; Palma JF
BMC Cancer; 2020 Sep; 20(1):885. PubMed ID: 32933495
[TBL] [Abstract][Full Text] [Related]
47. Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic.
Fernandes MGO; Sousa C; Pereira Reis J; Cruz-Martins N; Souto Moura C; Guimarães S; Justino A; Pina MJ; Magalhães A; Queiroga H; Marques JA; Machado JC; Costa JL; Hespanhol V
Cells; 2021 Jul; 10(8):. PubMed ID: 34440680
[TBL] [Abstract][Full Text] [Related]
48. Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms.
Cowzer D; Shah RH; Chou JF; Kundra R; Punn S; Fiedler L; DeMore A; Capanu M; Berger MF; Reidy-Lagunes D; Raj N
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38252063
[TBL] [Abstract][Full Text] [Related]
49. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
Ohira T; Sakai K; Matsubayashi J; Kajiwara N; Kakihana M; Hagiwara M; Hibi M; Yoshida K; Maeda J; Ohtani K; Nagao T; Nishio K; Ikeda N
Cancer Sci; 2016 Nov; 107(11):1660-1666. PubMed ID: 27575703
[TBL] [Abstract][Full Text] [Related]
50. Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA.
Xiang Z; Wan R; Zou B; Qi X; Huang Q; Kumar S; Pitman JL; Zhou G; Song Q
Anal Bioanal Chem; 2018 Oct; 410(26):6751-6759. PubMed ID: 30128808
[TBL] [Abstract][Full Text] [Related]
51. Validation of a next-generation sequencing assay for the detection of EGFR mutations in cell-free circulating tumor DNA.
Stitz R; Buder A; Silye R; Baumgartner B; Pühringer F; Filipits M; Oberndorfer E; Heitzer E
Exp Mol Pathol; 2021 Dec; 123():104685. PubMed ID: 34560086
[TBL] [Abstract][Full Text] [Related]
52. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.
Supplee JG; Milan MSD; Lim LP; Potts KT; Sholl LM; Oxnard GR; Paweletz CP
Lung Cancer; 2019 Aug; 134():96-99. PubMed ID: 31320002
[TBL] [Abstract][Full Text] [Related]
53. Sputum cell-free DNA for detection of alterations of multiple driver genes in lung adenocarcinoma.
Wang Z; Li L; Wang Y; Li X; Xu Y; Wang M; Liang L; Wu X; Tang M; Li Y; He S; Du J; He L; Sun M; Yang L; Di J; Gai F; Liu D
Cancer Cytopathol; 2023 Feb; 131(2):110-116. PubMed ID: 36103360
[TBL] [Abstract][Full Text] [Related]
54. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
[TBL] [Abstract][Full Text] [Related]
55. Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.
Yang CY; Shih JY; Liao WY; Ho CC; Hsu CL; Tsai TH; Wu SG; Lin YT; Hsu WH; Jain S; Olsen S; Yang JC; Yu CJ; Yang PC
Eur J Cancer; 2023 Nov; 193():113310. PubMed ID: 37722270
[TBL] [Abstract][Full Text] [Related]
56. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.
Sabari JK; Offin M; Stephens D; Ni A; Lee A; Pavlakis N; Clarke S; Diakos CI; Datta S; Tandon N; Martinez A; Myers ML; Makhnin A; Leger Y; Yu HA; Paik PK; Chaft JE; Kris MG; Jeon JO; Borsu LA; Ladanyi M; Arcila ME; Hernandez J; Henderson S; Shaffer T; Garg K; DiPasquo D; Raymond CK; Lim LP; Li M; Hellmann MD; Drilon A; Riely GJ; Rusch VW; Jones DR; Rimner A; Rudin CM; Isbell JM; Li BT
J Natl Cancer Inst; 2019 Jun; 111(6):575-583. PubMed ID: 30496436
[TBL] [Abstract][Full Text] [Related]
57. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
Paweletz CP; Sacher AG; Raymond CK; Alden RS; O'Connell A; Mach SL; Kuang Y; Gandhi L; Kirschmeier P; English JM; Lim LP; Jänne PA; Oxnard GR
Clin Cancer Res; 2016 Feb; 22(4):915-22. PubMed ID: 26459174
[TBL] [Abstract][Full Text] [Related]
58. Developing an effective quality evaluation strategy of next-generation sequencing for accurate detecting non-small cell lung cancer samples with variable characteristics: a real-world clinical practice.
Rao W; Guo L; Ling Y; Dong L; Li W; Ying J; Li W
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4889-4897. PubMed ID: 36305947
[TBL] [Abstract][Full Text] [Related]
59. NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay.
Olbryt M; Rajczykowski M; Bal W; Fiszer-Kierzkowska A; Cortez AJ; Mazur M; Suwiński R; Widłak W
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356096
[TBL] [Abstract][Full Text] [Related]
60. The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.
Laufer-Geva S; Rozenblum AB; Twito T; Grinberg R; Dvir A; Soussan-Gutman L; Ilouze M; Roisman LC; Dudnik E; Zer A; Rotem O; Lanman RB; Peled N
J Thorac Oncol; 2018 Nov; 13(11):1705-1716. PubMed ID: 30121392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
